Shandong Xinhua Pharmaceutical Company Limited (HKG:0719)
8.05
+0.03 (0.37%)
Aug 19, 2025, 4:08 PM HKT
HKG:0719 Revenue
Shandong Xinhua Pharmaceutical Company had revenue of 2.43B CNY in the quarter ending March 31, 2025, a decrease of -1.81%. This brings the company's revenue in the last twelve months to 8.42B, up 6.12% year-over-year. In the year 2024, Shandong Xinhua Pharmaceutical Company had annual revenue of 8.47B with 4.51% growth.
Revenue (ttm)
8.42B CNY
Revenue Growth
+6.12%
P/S Ratio
1.17
Revenue / Employee
1.15M CNY
Employees
7,296
Market Cap
10.53B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 8.47B | 365.47M | 4.51% |
Dec 31, 2023 | 8.10B | 597.86M | 7.97% |
Jan 1, 2023 | 7.50B | 942.91M | 14.37% |
Dec 31, 2021 | 6.56B | 554.49M | 9.23% |
Dec 31, 2020 | 6.01B | 399.57M | 7.13% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 35.81B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 71.34B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
Sino Biopharmaceutical | 30.72B |
WuXi Biologics | 19.87B |
CSPC Pharmaceutical Group | 28.99B |